Related Experiment Videos
Anti-CD 40 monoclonal antibody.
1Cancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.
Leukemia & Lymphoma
|August 9, 2005
Summary
Monoclonal antibodies targeting CD 40 are a promising cancer therapy. These antibodies harness immune responses and directly attack cancer cells, showing potential in early clinical trials for various malignancies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- CD 40 and CD 154 interactions are crucial for adaptive immunity.
- CD 40 is expressed on various hematological and epithelial cancers.
- Targeting CD 40 offers a novel therapeutic strategy in oncology.
Purpose of the Study:
- To review the role of CD 40 in immune responses.
- To explore the therapeutic potential of anti-CD 40 monoclonal antibodies.
- To summarize early clinical trial data for CD 40-targeted therapies.
Main Methods:
- Review of existing literature on CD 40 biology and function.
- Analysis of mechanisms of action for anti-CD 40 antibodies.
- Compilation and summary of early-phase clinical trial results.
Main Results:
- Anti-CD 40 antibodies engage multiple anti-cancer mechanisms.
- These mechanisms include complement-dependent and antibody-dependent cellular cytotoxicity.
- Early clinical data suggest potential efficacy in treating malignancies.
Conclusions:
- Targeting CD 40 with monoclonal antibodies is a promising therapeutic avenue.
- Further clinical investigation is warranted to establish the efficacy and safety of these agents.
- CD 40-targeted therapies represent a potentially exciting new treatment approach for cancer.